Svb Leerink Comments on Synthorx Inc’s Q1 2019 Earnings (THOR)

Synthorx Inc (NASDAQ:THOR) – Svb Leerink issued their Q1 2019 EPS estimates for shares of Synthorx in a research report issued to clients and investors on Monday, March 18th. Svb Leerink analyst D. Graybosch anticipates that the medical instruments supplier will post earnings per share of ($0.30) for the quarter. Svb Leerink currently has a “Outperform” rating on the stock. Svb Leerink also issued estimates for Synthorx’s Q2 2019 earnings at ($0.30) EPS, Q3 2019 earnings at ($0.31) EPS, Q4 2019 earnings at ($0.46) EPS, FY2019 earnings at ($1.38) EPS, FY2020 earnings at ($1.79) EPS, FY2021 earnings at ($1.91) EPS, FY2022 earnings at ($1.93) EPS and FY2023 earnings at ($3.32) EPS.

THOR has been the subject of several other reports. Zacks Investment Research downgraded shares of Synthorx from a “buy” rating to a “hold” rating in a research report on Tuesday. Leerink Swann assumed coverage on shares of Synthorx in a research report on Friday, March 15th. They set an “outperform” rating for the company. HC Wainwright assumed coverage on shares of Synthorx in a research report on Wednesday, January 2nd. They set a “buy” rating and a $30.00 price objective for the company. Finally, Jefferies Financial Group assumed coverage on shares of Synthorx in a research report on Wednesday, January 2nd. They set a “buy” rating and a $21.00 price objective for the company. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. Synthorx presently has an average rating of “Buy” and a consensus price target of $23.67.



NASDAQ THOR opened at $21.31 on Wednesday. Synthorx has a 1-year low of $11.00 and a 1-year high of $23.53.

Synthorx (NASDAQ:THOR) last released its quarterly earnings results on Tuesday, March 12th. The medical instruments supplier reported ($0.89) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.77).

A number of institutional investors and hedge funds have recently made changes to their positions in the business. RA Capital Management LLC acquired a new position in Synthorx during the fourth quarter valued at approximately $169,014,000. Orbimed Advisors LLC acquired a new position in Synthorx during the fourth quarter valued at approximately $92,398,000. FMR LLC acquired a new position in Synthorx during the fourth quarter valued at approximately $38,559,000. Matisse Capital acquired a new position in Synthorx during the fourth quarter valued at approximately $956,000. Finally, Dean Capital Investments Management LLC acquired a new position in Synthorx during the fourth quarter valued at approximately $827,000. Institutional investors and hedge funds own 64.69% of the company’s stock.

Synthorx Company Profile

Synthorx, Inc, a biotechnology company, discovers and develops protein therapeutics. The company's lead product candidate is THOR-707, a variant of IL-2 that is in development in various tumor types as a single agent and in combination with an immune checkpoint inhibitor. The company was founded in 2014 and is headquartered in La Jolla, California.

Featured Story: Roth IRA

Receive News & Ratings for Synthorx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synthorx and related companies with MarketBeat.com's FREE daily email newsletter.